# Dr. Reddy's Laboratories Limited share price today (Dr. Reddy's Laboratories Limited, RDY)

> Dr. Reddy's Laboratories Limited's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. RDY · Healthcare · Drug Manufacturers - Specialty & Generic · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/rdy

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting worse, from fewer quarters than usual
- Price: $14.30 (+7.6% in a year)
- P/E: 40.4×, against its own history
- Revenue (Sep 2026): INR 86.7 B (−1.5% on a year ago)
- Profit (Sep 2026): INR 9.3 B (−35.6% on a year ago)
- Operating margin: 14.7% (−5.6 points on a year ago)
- ROE: 11%, FY26
- ROIC: 6.2%, against a 5.6% cost of capital: +0.6 points

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Dr. Reddy's Laboratories Limited share price today? Dr. Reddy's Laboratories Limited's share price was $14.30 at the close on 3 November 2026. It has been stalling near its high for 3 weeks. That is 8.1% above its average price over the last 200 trading days. In the last 52 weeks it traded between $12 and $15, and at that close it sat 70% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 4 weeks in a row. Over the last 10 years the share price moved +33% while the S&P 500 moved +255%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Dr. Reddy's Laboratories Limited pay? Dr. Reddy's Laboratories Limited declared INR 8.00 per local share for Mar 2026. It reports in Indian rupees, and one US-listed share can stand for several local shares, so we do not set this against the dollar price or show a yield. ## Which stock lists is Dr. Reddy's Laboratories Limited on? Dr. Reddy's Laboratories Limited is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Dr. Reddy's Laboratories Limited profitable? Dr. Reddy's Laboratories Limited earned INR 9.3 B of net profit in the Sep 2026 quarter, −35.6% on the same quarter a year earlier. Full-year FY26 profit was INR 42.9 B. Over 4 years profit has grown 16.1% a year on average. That is 10.7% of the quarter's revenue. The same quarter a year earlier earned INR 14.4 B. For the full year, FY26 profit was INR 42.9 B (−24.2% on the year before). Why profit moved: revenue changed −1.5% on a year earlier and the margin moved −5.6 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed −51.2% and revenue −3.6%. Profit is growing slower than sales: rising costs are taking part of the growth. This company reports in Indian rupees, not US dollars, so the money charts are left out here. The figures in the text are in that currency (INR); nothing is converted. ## How much revenue does Dr. Reddy's Laboratories Limited make, and is it growing? Dr. Reddy's Laboratories Limited reported INR 86.7 B of revenue in the Sep 2026 quarter, −1.5% on the same quarter a year earlier. Over 4 years it has grown 11.9% a year on average. The last full year, FY26, came in at INR 336 B. The last four reported quarters add to INR 330 B. The quarterly figures for FY22 do not add up to the full-year total on file, so those quarters are left out of the charts and sums. FY26 revenue was INR 336 B, +3.2% on the year before. Recent pace: the last four quarters grew −3.6% on average, against 11.9% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −3.6%, against +4.9% a year over the last 8 quarters (rolling over); profit over the last 12 months grew −52.3%, against −27.6% a year (rolling over). This company reports in Indian rupees, not US dollars, so the money charts are left out here. The figures in the text are in that currency (INR); nothing is converted. ## How much of its sales does Dr. Reddy's Laboratories Limited keep? Dr. Reddy's Laboratories Limited's operating margin was 14.7% in the Sep 2026 quarter, 5.6 percentage points lower than the same quarter a year ago. Across 5 years it has been between 14.7% and 23.4%. The latest quarter is within that range. Why the margin moved: operating margin changed −5.6 percentage points on the year while gross margin changed −2.6 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Dr. Reddy's Laboratories Limited's profit turning into cash? Over the last 3 years, 96% of Dr. Reddy's Laboratories Limited's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in INR 56.8 B of operating cash against INR 42.9 B of profit. After INR 23.3 B of spending on assets, INR 33.4 B was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. This company reports in Indian rupees, not US dollars, so the money charts are left out here. The figures in the text are in that currency (INR); nothing is converted. ## Where does Dr. Reddy's Laboratories Limited's cash go? Dr. Reddy's Laboratories Limited does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent INR 67.2 B on assets over the last 3 years. Averaged over those years that is 6.7% of FY26 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: INR 67.2 B over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. This company reports in Indian rupees, not US dollars, so the money charts are left out here. The figures in the text are in that currency (INR); nothing is converted. ## What is Dr. Reddy's Laboratories Limited's P/E ratio, and how does it compare with its own history? Dr. Reddy's Laboratories Limited's P/E is 40.4×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the Dr. Reddy's Laboratories Limited business getting better or worse? Dr. Reddy's Laboratories Limited's business is getting worse. Revenue and profit growth are shrinking: revenue growth is −3.6% in the latest quarter, against +16.6% at its best in 12 quarters, with ROCE falling at 7.8%. This is based on 12 quarters of 3 measures, with some gaps. Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind. This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution. ## How much does Dr. Reddy's Laboratories Limited earn on its capital? Dr. Reddy's Laboratories Limited earned a ROE of 11% in FY26. Its return on capital used (ROIC) is 0.6 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 12.8% net margin and 0.58× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 12.8% net margin × 0.58× asset turnover × 1.52× leverage (assets divided by equity) ≈ 11.3% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 6.2% − 5.6% = +0.6 percentage points. The 5.6% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error. The 6.2% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 11.0%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Dr. Reddy's Laboratories Limited have too much debt? Dr. Reddy's Laboratories Limited has total debt of INR 72.3 B against shareholder equity of INR 389 B as of Sep 2026, so its debt is 0.19× its equity, which is very little. Year by year, that ratio went from 0.18 in FY22 to 0.20 in FY26. So the returns on this page come from the business, not from borrowed money. This company reports in Indian rupees, not US dollars, so the money charts are left out here. The figures in the text are in that currency (INR); nothing is converted. ## What is the Dr. Reddy's Laboratories Limited shareholding pattern? We have no ownership or short-position figures for Dr. Reddy's Laboratories Limited, so this section says so rather than fill the gap. At normal trading volumes, closing those positions would take about 8.2 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. ## How far is Dr. Reddy's Laboratories Limited from balance-sheet trouble? For Dr. Reddy's Laboratories Limited, the Z-score is 5.29. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 5.29 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Dr. Reddy's Laboratories Limited rank in its industry? There is no score against its industry: Dr. Reddy's Laboratories Limited is not among the largest members shown in this industry comparison for Drug Manufacturers - Specialty & Generic. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Dr. Reddy's Laboratories Limited compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Dr. Reddy's Laboratories Limited in size? Dr. Reddy's Laboratories Limited is the 9th largest of 51 Drug Manufacturers - Specialty & Generic companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Viatris Inc., Neurocrine Biosciences, Inc. and Elanco Animal Health Incorporated. Just below it: Alkermes plc, Kiniksa Pharmaceuticals International, plc and Amneal Pharmaceuticals, Inc. ### Drug Manufacturers - Specialty & Generic companies close in size

1. [Viatris Inc.](https://www.sectoralpha.in/us/stocks/vtrs) $21.7 billion
2. [Neurocrine Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/nbix) $16.8 billion
3. [Elanco Animal Health Incorporated](https://www.sectoralpha.in/us/stocks/elan) $12.3 billion
4. Dr. Reddy's Laboratories Limited $12 billion
5. [Alkermes plc](https://www.sectoralpha.in/us/stocks/alks) $7.7 billion
6. [Kiniksa Pharmaceuticals International, plc](https://www.sectoralpha.in/us/stocks/knsa) $7.3 billion
7. [Amneal Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/amrx) $7 billion

[All 51 Drug Manufacturers - Specialty & Generic companies, largest first](https://www.sectoralpha.in/us/sectors/drug-manufacturers-specialty-generic#all-companies)

### Companies close in size in other industries

1. [Paycom Software, Inc.](https://www.sectoralpha.in/us/stocks/payc) $11.8 billion · Software - Application
2. [Gaming and Leisure Properties, Inc.](https://www.sectoralpha.in/us/stocks/glpi) $11.8 billion · REIT - Specialty
3. Dr. Reddy's Laboratories Limited $11.8 billion
4. [HubSpot, Inc.](https://www.sectoralpha.in/us/stocks/hubs) $11.7 billion · Software - Application
5. [DaVita Inc.](https://www.sectoralpha.in/us/stocks/dva) $11.7 billion · Medical Care Facilities

## What else do people ask about Dr. Reddy's Laboratories Limited? ### What is Dr. Reddy's Laboratories Limited Limited's stock price today? Dr. Reddy's Laboratories Limited's stock price is $14.30, +7.6% over the past year. The whole company is worth $12.0 B on the market. In the last 52 weeks it traded between $12 to $15; today it is 70% of the way up from the low, 8.1% above its 200-day average (as of 3 November 2026). ### What were Dr. Reddy's Laboratories Limited Limited's latest quarterly results? Dr. Reddy's Laboratories Limited reported revenue of INR 86.7 B and net profit of INR 9.3 B for the Sep 2026 quarter. Revenue fell 1.5% and profit fell 35.6% compared with a year earlier. The operating margin was 14.7%, 5.6 percentage points lower than a year earlier (as of 3 November 2026). ### What is Dr. Reddy's Laboratories Limited Limited's market cap? Dr. Reddy's Laboratories Limited's market capitalisation is $12.0 B at a stock price of $14.30. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Dr. Reddy's Laboratories Limited Limited performing? Dr. Reddy's Laboratories Limited's share price has been stalling near its high for 3 weeks. In its latest quarter, revenue fell 1.5% and profit fell 35.6% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 4 weeks running (as of 3 November 2026). ### Will Dr. Reddy's Laboratories Limited Limited's stock price go up? This page does not forecast Dr. Reddy's Laboratories Limited's stock price. What it shows instead: the stock price is $14.30, and it has been stalling near its high for 3 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Where is Dr. Reddy's Laboratories Limited Limited in its business cycle? Dr. Reddy's Laboratories Limited's FY26 operating margin was 14.7%, against a 5-year range of 14.7% to 23.4%: the low end of its own range, which is often where recoveries start. The latest quarter was 14.7%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Dr. Reddy's Laboratories Limited Limited story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Dr. Reddy's Laboratories Limited Limited a stock worth studying right now? What the numbers show: Dr. Reddy's Laboratories Limited's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.